Q BioMed Inc.
QBIO · OTC
2/28/2023 | 11/30/2022 | 8/31/2022 | 5/31/2022 | |
|---|---|---|---|---|
| Revenue | $3 | $13 | $26 | $170 |
| % Growth | -80.1% | -52.3% | -84.6% | – |
| Cost of Goods Sold | $3 | $80 | $66 | $73 |
| Gross Profit | $0 | -$68 | -$40 | $98 |
| % Margin | 0% | -539.8% | -152.9% | 57.3% |
| R&D Expenses | $3 | $22 | $21 | $13 |
| G&A Expenses | $440 | $476 | $720 | $1,019 |
| SG&A Expenses | $440 | $476 | $720 | $1,019 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$4 | $0 |
| Operating Expenses | $443 | $498 | $741 | $1,032 |
| Operating Income | -$445 | $2,582 | -$781 | -$934 |
| % Margin | -17,800.4% | 20,597.2% | -2,973.2% | -548.1% |
| Other Income/Exp. Net | -$277 | $2,868 | -$14 | -$336 |
| Pre-Tax Income | -$722 | $2,302 | -$795 | -$1,270 |
| Tax Expense | $105 | $0 | $14 | $0 |
| Net Income | -$826 | $2,302 | -$810 | -$1,892 |
| % Margin | -33,056.4% | 18,368.3% | -3,081.3% | -1,110% |
| EPS | -0.008 | 0.051 | -0.018 | -0.057 |
| % Growth | -114.8% | 385.6% | 68.6% | – |
| EPS Diluted | -0.008 | 0.051 | -0.018 | -0.057 |
| Weighted Avg Shares Out | 108,730 | 44,827 | 44,898 | 33,005 |
| Weighted Avg Shares Out Dil | 108,730 | 44,827 | 44,898 | 33,005 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $277 | $276 | $240 | $454 |
| Depreciation & Amortization | $13 | $13 | $13 | $13 |
| EBITDA | -$433 | -$553 | -$543 | -$804 |
| % Margin | -17,300.4% | -4,412.4% | -2,066.8% | -471.6% |